Exact Sciences' Q3 Revenues Up; Loss Rises on Increased Expenses | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported that its third-quarter revenues rose around 8 percent and its net loss more than tripled as the firm significantly upped its investment in R&D.

The Madison, Wis.-based molecular diagnostics firm brought in total revenues of $1.4 million for the three-month period ended Sept. 30, compared to $1.3 million for the third quarter of 2009. Nearly all of its revenues came from license fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.